378 related articles for article (PubMed ID: 18416598)
1. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
2. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
3. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
5. Lack of cross-resistance between prednisolone and methotrexate in childhood acute lymphoblastic leukemia? A preliminary analysis.
Hegge IR; Kaspers GJ; Rots MG; Jansen G; Pieters R; Veerman AJ
Adv Exp Med Biol; 1999; 457():551-5. PubMed ID: 10500833
[TBL] [Abstract][Full Text] [Related]
6. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
8. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
[TBL] [Abstract][Full Text] [Related]
9. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
10. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia.
Dördelmann M; Reiter A; Zimmermann M; Fengler R; Henze G; Riehm H; Schrappe M
J Pediatr Hematol Oncol; 1998; 20(5):444-50. PubMed ID: 9787317
[TBL] [Abstract][Full Text] [Related]
11. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
12. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
14. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
17. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.
Thyss A; Suciu S; Bertrand Y; Mazingue F; Robert A; Vilmer E; Mechinaud F; Benoit Y; Brock P; Ferster A; Lutz P; Boutard P; Marguerite G; Plouvier E; Michel G; Plantaz D; Munzer M; Rialland X; Chantraine JM; Norton L; Solbu G; Philippe N; Otten J
J Clin Oncol; 1997 May; 15(5):1824-30. PubMed ID: 9164191
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
Wang H; Chi ZF; Li S; Wang XL; Hao LC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation.
Hill JM; Kornblith AB; Jones D; Freeman A; Holland JF; Glicksman AS; Boyett JM; Lenherr B; Brecher ML; Dubowy R; Kung F; Maurer H; Holland JC
Cancer; 1998 Jan; 82(1):208-18. PubMed ID: 9428499
[TBL] [Abstract][Full Text] [Related]
20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
